Cannabis products may interact with common pediatric medications by inhibiting drug-metabolizing enzymes
Analysis of case reports and FDA adverse event data found potential cannabis-drug interactions in children, particularly with methadone, everolimus, fluoxetine, and paroxetine.
Quick Facts
What This Study Found
Seven published case reports and 9,142 FAERS adverse event reports identified potential interactions between cannabis/cannabinoids and pediatric medications; cannabinoids may inhibit cytochrome P450 enzymes, increasing drug exposure and ADR risk.
Key Numbers
7 published case reports; 9,142 FAERS adverse event reports; interactions flagged with methadone, everolimus, fluoxetine, and paroxetine.
How They Did This
Literature search (PubMed) for published case reports and FAERS database analysis of adverse event reports involving cannabis/cannabinoids in patients under 18; Drug Interaction Probability Scale assessed causality in case reports.
Why This Research Matters
As CBD and cannabis products become more common in pediatric settings (especially for epilepsy), understanding their potential to alter the metabolism of co-prescribed medications is a safety priority.
The Bigger Picture
Pediatric patients on multiple medications are particularly vulnerable to drug interactions, and the growing use of cannabinoid products in this population warrants systematic pharmacovigilance.
What This Study Doesn't Tell Us
Case reports cannot establish causation; FAERS data relies on voluntary reporting and may undercount events; limited pediatric-specific pharmacokinetic data for cannabinoids.
Questions This Raises
- ?What are the specific enzyme inhibition profiles of CBD and THC at pediatric doses?
- ?Should routine drug interaction screening include cannabinoid products?
- ?Are there age-dependent differences in interaction risk?
Trust & Context
- Key Stat:
- 9,142 adverse event reports involving cannabis/cannabinoids in pediatric patients
- Evidence Grade:
- Pharmacovigilance approach using case reports and FAERS data provides safety signals but cannot establish causation or quantify interaction magnitude.
- Study Age:
- Published 2025
- Original Title:
- Part 1: Evaluation of Pediatric Cannabis-Drug Interaction Reports.
- Published In:
- Pharmacology research & perspectives, 13(1), e70046 (2025)
- Authors:
- Chapin, Maryann R, Kane-Gill, Sandra L, Li, Xiaotong, Abanyie, Kojo, Taneja, Sanya B, Egbert, Susan, Paine, Mary F, Boyce, Richard D
- Database ID:
- RTHC-06184
Evidence Hierarchy
Summarizes existing research on a topic.
What do these levels mean? →Frequently Asked Questions
What medications might interact with cannabis in children?
The study flagged potential interactions with methadone, everolimus, fluoxetine, and paroxetine, driven by cannabinoid inhibition of drug-metabolizing enzymes.
How do cannabis products cause drug interactions?
Cannabinoids can inhibit several cytochrome P450 enzymes that metabolize other medications, potentially leading to higher drug levels and increased side effect risk.
Read More on RethinkTHC
- CBD-oil-quality-guide
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-epilepsy-CBD-Epidiolex
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- medical-benefits-of-cannabis
- quitting-weed-before-surgery
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- seniors-older-adults-cannabis-risks-medications
- weed-breastfeeding-THC-breast-milk
Cite This Study
https://rethinkthc.com/research/RTHC-06184APA
Chapin, Maryann R; Kane-Gill, Sandra L; Li, Xiaotong; Abanyie, Kojo; Taneja, Sanya B; Egbert, Susan; Paine, Mary F; Boyce, Richard D. (2025). Part 1: Evaluation of Pediatric Cannabis-Drug Interaction Reports.. Pharmacology research & perspectives, 13(1), e70046. https://doi.org/10.1002/prp2.70046
MLA
Chapin, Maryann R, et al. "Part 1: Evaluation of Pediatric Cannabis-Drug Interaction Reports.." Pharmacology research & perspectives, 2025. https://doi.org/10.1002/prp2.70046
RethinkTHC
RethinkTHC Research Database. "Part 1: Evaluation of Pediatric Cannabis-Drug Interaction Re..." RTHC-06184. Retrieved from https://rethinkthc.com/research/chapin-2025-part-1-evaluation-of
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.